Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Uncontrolled Hypertension Clear all
Completed Not applicable Interventional Results available

Measuring Adherence to Control Hypertension

NCT01257347
View directory record Official record
Conditions
Hypertension
Interventions
Disclosure of adherence report to clinician, MedSignals pillbox
Behavioral · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

NCT01338636
View directory record Official record
Conditions
Exercise-induced Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 28, 2026, 3:50 PM EDT
Terminated Not applicable Interventional Results available

Impact of Renal SympAthetic DenerVation on Chronic HypErtension

NCT01628198
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
Device
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Not applicable Interventional

Use of Automated Office Blood Pressure Monitoring

NCT05395403
View directory record Official record
Conditions
Hypertension, Uncontrolled Hypertension, Hypertension, White Coat, Hypertension, Resistant to Conventional Therapy
Interventions
Blood pressure measurement device
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Not applicable Interventional

SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension

NCT01418261
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Renal denervation (Symplicity Catheter System), Renal angiogram
Device · Diagnostic Test
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
79
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Phase 3 Interventional

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

NCT02007629
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Not applicable Interventional

How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?

NCT02627352
View directory record Official record
Conditions
Glaucoma
Interventions
Micropulse Transscleral Cyclophotocoagulation
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Phase 4 Interventional

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

NCT00562809
View directory record Official record
Conditions
Hypertension
Interventions
IRBESARTAN
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 26, 2007 · Synced Sep 28, 2026, 3:50 PM EDT
Active, not recruiting Not applicable Interventional

REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /

NCT05372679
View directory record Official record
Conditions
Uncontrolled Stage 2 Hypertension
Interventions
Renal denervation
Device
Lead sponsor
SoniVie Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 28, 2026, 3:50 PM EDT
Enrolling by invitation Not applicable Interventional

Engaging Patients in Adherence Interventions Using Behavioral Science

NCT06543394
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Primer postcard, Control recruitment letter, Behavioral theory-informed recruitment letter, 2 phone calls, 4 phone calls
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Not applicable Interventional

Using Bluetooth Home Blood Pressure Monitors With Pharmacist Interventions

NCT05606783
View directory record Official record
Conditions
Hypertension
Interventions
Telehealth Follow-up Visits, Surveys, Devices
Behavioral · Device
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Patients With Uncontrolled Hypertension

NCT05137002
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 28, 2026, 3:50 PM EDT
Active, not recruiting Phase 3 Interventional

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430
View directory record Official record
Conditions
Hypertension
Interventions
lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
128
States / cities
Birmingham, Alabama • Foley, Alabama • Chandler, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Not applicable Interventional

Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4

NCT01972139
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Renal Denervation using the Symplicity Renal Denervation System, Sham Renal Denervation, Renal Angiography
Device · Other
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

NCT06153693
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
87
States / cities
Alexander City, Alabama • Birmingham, Alabama • Foley, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT06034743
View directory record Official record
Conditions
Uncontrolled Hypertension, Resistant Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Saraland, Alabama • Scottsdale, Arizona • Sun City West, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 28, 2026, 3:50 PM EDT
Not yet recruiting Not applicable Interventional

Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension

NCT07218198
View directory record Official record
Conditions
Hypertension, Hypertension (HTN), Blood Pressure, High, Blood Pressure Control
Interventions
Standard medical treatment, Clinical Decision Support Tool
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 28, 2026, 3:50 PM EDT
Terminated Not applicable Interventional Results available

EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension

NCT01903187
View directory record Official record
Conditions
Hypertension
Interventions
EnligHTN Renal Denervation, Sham
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 28, 2026, 3:50 PM EDT
Recruiting No phase listed Observational

Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic

NCT07232017
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
IN-HOME BP
Other
Lead sponsor
Anita Misra-Hebert
Other
Eligibility
18 Years to 85 Years
Enrollment
1,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 28, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

NCT05001945
View directory record Official record
Conditions
Hypertension, Renal
Interventions
MLS-101 (Part I), Placebo (Part I), Placebo (Part II), MLS-101 (Part II)
Drug · Other
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
44
States / cities
Lincoln, California • Torrance, California • Tustin, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 28, 2026, 3:50 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

NCT01602367
View directory record Official record
Conditions
Hypertension
Interventions
BMS-823778, Placebo matching with BMS-823778
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
22
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 28, 2026, 3:50 PM EDT
Active, not recruiting Not applicable Interventional Results available

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

NCT03614260
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Paradise Renal Denervation System, Renal Angiogram
Device · Procedure
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 3:50 PM EDT
Recruiting No phase listed Observational

Global Paradise System US Post Approval Study

NCT06297291
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
Paradise Ultrasound Renal Denervation Treatment
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 28, 2026, 3:50 PM EDT